Suppr超能文献

端粒功能障碍在髓系恶性肿瘤中的生物学及临床意义

Biological and clinical implications of telomere dysfunction in myeloid malignancies.

作者信息

Kishtagari Ashwin, Watts Justin

机构信息

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, OH, USA.

Division of Hematology, Department of Medicine, University of Miami, Miller School of Medicine, Sylvester Comprehensive Cancer Center, 1475 NW 12th Avenue, Miami, FL 33136-1002, USA.

出版信息

Ther Adv Hematol. 2017 Nov;8(11):317-326. doi: 10.1177/2040620717731549. Epub 2017 Oct 6.

Abstract

Telomeres at the ends of linear chromosomes protect the genome. Telomeres shorten with each round of cell division, placing a finite limit on cell growth. Telomere attrition is associated with cell senescence and apoptosis. Telomerase, a specialized ribonucleoprotein complex, maintains telomeres homeostasis through repeat addition of telomere sequences to the 3' telomeric overhang. Telomere biology is closely related to cancer and normal aging. Upregulation of telomerase or activation of the alternative pathway of telomere lengthening is a hallmark of cancer cells, making telomerase an attractive target for cancer therapeutics. In this review, we will discuss telomere biology and the prognostic implications of telomere length in acute myeloid leukemia, and review exciting new investigational approaches using telomerase inhibitors in acute myeloid leukemia and other myeloid malignancies.

摘要

线性染色体末端的端粒保护基因组。端粒随着每一轮细胞分裂而缩短,对细胞生长设置了有限的限制。端粒损耗与细胞衰老和凋亡相关。端粒酶是一种特殊的核糖核蛋白复合体,通过向3'端粒突出端重复添加端粒序列来维持端粒稳态。端粒生物学与癌症和正常衰老密切相关。端粒酶的上调或端粒延长替代途径的激活是癌细胞的一个标志,使得端粒酶成为癌症治疗的一个有吸引力的靶点。在这篇综述中,我们将讨论端粒生物学以及端粒长度在急性髓系白血病中的预后意义,并综述在急性髓系白血病和其他髓系恶性肿瘤中使用端粒酶抑制剂的令人兴奋的新研究方法。

相似文献

1
Biological and clinical implications of telomere dysfunction in myeloid malignancies.
Ther Adv Hematol. 2017 Nov;8(11):317-326. doi: 10.1177/2040620717731549. Epub 2017 Oct 6.
2
Telomerase and telomere biology in hematological diseases: A new therapeutic target.
Leuk Res. 2017 May;56:60-74. doi: 10.1016/j.leukres.2017.02.002. Epub 2017 Feb 7.
3
Telomeric 3'-overhang length is associated with the size of telomeres.
Exp Gerontol. 2008 Apr;43(4):258-65. doi: 10.1016/j.exger.2008.01.005. Epub 2008 Jan 26.
4
Telomere protein complexes and their role in lymphoid malignancies.
Front Biosci (Schol Ed). 2017 Jan 1;9(1):17-30. doi: 10.2741/s469.
5
Telomerase-based therapies in haematological malignancies.
Cell Biochem Funct. 2022 Mar;40(2):199-212. doi: 10.1002/cbf.3687. Epub 2022 Feb 1.
6
Telomere and telomerase biology.
Prog Mol Biol Transl Sci. 2014;125:1-40. doi: 10.1016/B978-0-12-397898-1.00001-3.
7
Alternative Lengthening of Telomeres in the Budding Yeast .
G3 (Bethesda). 2019 Oct 7;9(10):3345-3358. doi: 10.1534/g3.119.400428.
8
Critically short telomeres in acute myeloid leukemia with loss or gain of parts of chromosomes.
Genes Chromosomes Cancer. 2006 Mar;45(3):247-56. doi: 10.1002/gcc.20286.
9
Telomeres and telomerase in human health and disease.
J Pediatr Endocrinol Metab. 2002 Mar;15(3):229-40. doi: 10.1515/jpem.2002.15.3.229.
10
Telomeres and marrow failure.
Hematology Am Soc Hematol Educ Program. 2009:338-43. doi: 10.1182/asheducation-2009.1.338.

引用本文的文献

3
Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies.
Cancers (Basel). 2021 Feb 4;13(4):612. doi: 10.3390/cancers13040612.
4
Telomere Length and Hematological Disorders: A Review.
In Vivo. 2020 Nov-Dec;34(6):3093-3101. doi: 10.21873/invivo.12142.
5
Short Dysfunctional Telomere Is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients.
Int J Hematol Oncol Stem Cell Res. 2020 Jul 1;14(3):188-199. doi: 10.18502/ijhoscr.v14i3.3728.

本文引用的文献

2
Telomeres in cancer: tumour suppression and genome instability.
Nat Rev Mol Cell Biol. 2017 Mar;18(3):175-186. doi: 10.1038/nrm.2016.171. Epub 2017 Jan 18.
3
Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.
Acta Haematol. 2016;136(4):210-218. doi: 10.1159/000448160. Epub 2016 Sep 16.
4
Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia.
Leuk Res. 2016 Oct;49:62-5. doi: 10.1016/j.leukres.2016.07.013. Epub 2016 Jul 25.
6
Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis.
Blood Cancer J. 2016 Mar 11;6(3):e405. doi: 10.1038/bcj.2016.13.
7
8
Treating Myeloproliferation--On Target or Off?
N Engl J Med. 2015 Sep 3;373(10):965-6. doi: 10.1056/NEJMe1508740.
9
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.
N Engl J Med. 2015 Sep 3;373(10):920-8. doi: 10.1056/NEJMoa1503479.
10
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
N Engl J Med. 2015 Sep 3;373(10):908-19. doi: 10.1056/NEJMoa1310523.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验